Health Empire Corporation Valuation
Is HEALTH-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HEALTH-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HEALTH-R's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HEALTH-R's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HEALTH-R?
Other financial metrics that can be useful for relative valuation.
What is HEALTH-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿449.58m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 10x |
Enterprise Value/EBITDA | -6.7x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does HEALTH-R's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.9x | ||
SE-ED SE-Education | 0.4x | n/a | ฿791.7m |
BEAUTY Beauty Community | 3.4x | n/a | ฿1.5b |
SCM Successmore Being | 2.4x | n/a | ฿2.1b |
JUBILE Jubilee Enterprise | 1.7x | 7.8% | ฿2.5b |
HEALTH-R Health Empire Corporation | 13.9x | n/a | ฿449.6m |
Price-To-Sales vs Peers: HEALTH-R is expensive based on its Price-To-Sales Ratio (13.9x) compared to the peer average (1.9x).
Price to Earnings Ratio vs Industry
How does HEALTH-R's PE Ratio compare vs other companies in the TH Specialty Retail Industry?
Price-To-Sales vs Industry: HEALTH-R is expensive based on its Price-To-Sales Ratio (13.9x) compared to the TH Specialty Retail industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is HEALTH-R's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 13.9x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate HEALTH-R's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.